Dominate the $200 billion molecule-to-market roadmap.
“PEER™ has the potential to enable early identification of biologic therapeutics, drugs, or specific combinations of therapeutics from a panel of candidates that would be most effective for treating solid tumor cancers. This would revolutionize cancer drug R&D, by forming a bridge across the gap that divides standard in vitro and animal models in preclinical evaluation of formulations.”
- Dr. Lonnie Bookbinder CEO
CEO ARIZ Precision Medicine
Pharmaceutical companies invest considerable sums of money over a period of 10 or more years to bring a new cancer therapy to market. Each year, US pharmaceutical companies spend nearly $90 billion in preclinical research and clinical trials.
And yet, despite years of rigorous analysis, nearly 90% of formulations that succeed in preclinical evaluations, fail in clinical trials.
This is because cancer is not a monolithic disease. Although cancer is near ubiquitous, each tumor develops differently due to a variety of factors including genetic, environmental, and the inherent heterogeneity in tumor composition. Consequently, each tumor responds differently even to the same therapeutic. Evaluating therapeutic efficacy of preclinical formulations on established cell lines is therefore inadequate.
There is a critical, unmet, and urgent need to evaluate therapeutic efficacy of promising preclinical formulations in more representative patient tissue models.
Match preclinical formulations to tumors.
predicts clinical efficacy of preclinical formulations.
At CerFlux, we are developing Preclinical Estimated Efficacy Report (PEER™) technology to narrow and select preclinical formulations that are most likely to succeed in clinical trials. Multiple preclinical formulations can be analyzed simultaneously in PEER™ bioreactors to evaluate efficacy and resistance of each on a panel of biopsy tumor tissue for indication of interest.
PEER™ can be integrated into the preclinical workflow at any point following high throughput studies to determine which formulations would likely exhibit clinical efficacy and to what degree, thereby substantially reducing cost and time-to-market of much needed new cancer therapies.
Matching preclinical formulations to patient tumor tissue for indications of interest – before clinical trials – to bring life-saving cancer therapies to market faster and at a lower cost.